Page 130 - NobleCon21

Health Care
Date November 20, 2025 Health Care
52wk High $11.78
52wk Low $3.72 Nutriband Inc. NTRB $5.38
121 South Orange Avenue
Orlando, FL 32801

(USD - in millions) www.nutriband.com
Market Cap 61.9
Enterprise 55.2
Basic Shares Out. 12.02 COMPANY OVERVIEW
Float 3.98
Institutional Holdings 3.11% Detailed Analysis:Channelchek.com
Short Interest 0.11
Avg. 90-Day Volume 0.03 At Nutriband and our subsidiaries, our core focus is to use innovative
drug delivery systems and devices to improve patient outcomes,
specifically targeting the Global Opioid epidemic. Fentanyl and other
opioid-based transdermal medications unfortunately play a role in a
EPS Data significant number of opioid deaths each year with no solution currently
available. Working with our clinical subsidiary 4P Therapeutics, we
2022 2023 2024 have developed a technology called AVERSA, which we believe, with
CQ1 (0.08) N/A N/A FDA approval, will revolutionize the safety standard for these
CQ2 (0.12) N/A N/A medications and save countless lives per year.

CQ3 (0.14) N/A (0.12)
CQ4 (0.21) N/A (0.51)
CY (0.53) (0.69) (0.99) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.71
ROE (ttm) -98.00
Debt-to-Total Cap. (mrq) 3.08
Fiscal Year End 31-Jan

121 South OraOrlando FL 32801

Key Executives
CEO: Sheridan, Gareth
CFO: Goodman, Gerald
COO: Smith, Alan
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures